Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: Part I. formulation development, statistical optimization, and in vitro characterization

Pharmaceutical Research

Volumn 31, Issue 4, 2014, Pages 923-945

  Jain, Amit K ^a   Thanki, Kaushik ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

dual drug loading; lyophilization; quercetin; SNEDDS; tamoxifen

Indexed keywords

AEROSIL; ALCOHOL; CAPTEX; COSURFACTANT; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; ETHYLENE GLYCOL; GELUCIRE; LABRAFIL 1944 CS; OCTANOIN; PACEOL; PLUROL; POLOXAMER; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; PROPYLENE GLYCOL; QUERCETIN; TAMOXIFEN; UNCLASSIFIED DRUG; EMULSIFYING AGENT; NANOPARTICLE;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG UPTAKE; FREEZE DRYING; IN VITRO STUDY; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; CACO 2 CELL LINE; CHEMISTRY; COMBINATORIAL CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; FREEZE DRYING; HUMANS; NANOPARTICLES;

EID: 84897067828     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1213-2     Document Type: Article

References (62)

1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-13.
2. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751.
3. Boots AW, Haenen G, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-37.
4. Piantelli M, Maggiano N, Ricci R, Larocca LM, Capelli A, Scambia G, et al. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol. 1995;105(2):248-53.
5. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87(4):595-600.
6. Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, et al. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006;27(12):2424-33.
7. Ma ZS, Thanh HOAH, Chee Pang NG, Phuc Tien DO, Thanh HN, Hung H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004;24(5):1297-304.
8. Brookes PS, Digerness SB, Parks DA, Darley-Usmar V. Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. Free Radic Biol Med. 2002;32(11):1220-8.
9. Liu S, Hou W, Yao P, Li N, Zhang B, Hao L, et al. Heme oxygenase-1 mediates the protective role of quercetin against ethanol-induced rat hepatocytes oxidative damage. Toxicol In Vitro. 2012;26(1):74-80.
10. Gupta C, Vikram A, Tripathi DN, Ramarao P, Jena GB. Antioxidant and antimutagenic effect of quercetin against DEN induced hepatotoxicity in rat. Phytother Res. 2010;24(1):119-28.
11. Abo-Salem OM, Abd-Ellah MF, Ghonaim MM. Hepatoprotective activity of quercetin against acrylonitrile induced hepatotoxicity in rats. J Biochem Mol Toxicol. 2011;25(6):386-92.
12. Tabassum H, Parvez S, Rehman H, Banerjee BD, Raisuddin S. Catechin as an antioxidant in liver mitochondrial toxicity: inhibition of tamoxifen induced protein oxidation and lipid peroxidation. J Biochem Mol Toxicol. 2007;21(3):110-7.
13. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr. 2006;136(11):2715-21.
14. Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, et al. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol. 1997;17(1):51-9.
15. Lama G, Angelucci C, Bruzzese N, Nori SL, D'Atri S, Turriziani M, et al. Sensitivity of human melanoma cells to Oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression? Melanoma Res. 1998;8(4):313-22.
16. McVie JG, Simonetti GP, Stevenson D, Briggs RJ, Guelen PJ, de Vos D. The bioavailability of tamoplex (tamoxifen). part 1. A pilot study. Methods Find Exp Clin Pharmacol. 1986;8(8):505-12.
17. Tukker JJ, Blankenstein MA, Nortier JW. Comparison of bioavailability in man of tamoxifen after oral and rectal administration. J Pharm Pharmacol. 1986;38(12):888-92.
18. Martin EA, Rich KJ, White INH, Woods KL, Powles TJ, Smith LL. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 1995;16(7):1651-4.
19. Lettéron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol. 1990;39(12):2027-34.
20. Spencer JPE, Chowrimootoo G, Choudhury R, Debnam ES, Srai SK, Rice-Evans C. The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Lett. 1999;458(2):224-30.
21. van Leeuwen R, Brundel D, Neef C, van Gelder T, Mathijssen R, Burger D, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071-8.
22. Thanki K, Gangawal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Rel. 2013;170(1):15-40.
23. Hu C-MJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104-11.
24. Zhigaltsev IV, Maurer N, Akhong Q-F, Leone R, Leng E, Wang J, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Rel. 2005;104(1):103-11.
25. Bayne WF, Mayer LD, Swenson CE. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci. 2009;98(7):2540-8.
26. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharmaceutics. 2011;8(3):852-66.
27. Acharya S, Sahoo SK. Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials. 2011;32(24):5643-62.
28. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, et al. Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle-Aptamer Bioconjugates. Chemmedchem. 2007;2(9):1268-71.
29. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009;37(3):300-5.
30. Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials. 2009;30(20):3466-75.
31. Krakovičová H, Etrych T, Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur J Pharm Sci. 2009;37(3):405-12.
32. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673-7.
33. Kaneshiro TL, Lu Z-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30(29):5660-6.
34. Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy and drug induced toxicity. Mol Pharmaceutics. 2013. doi: 10.1021/mp400311j.
35. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25(1):47-58.
36. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11:S93-8.
37. Talegaonkar S, Jain S, Bhusinge U. Nano-colloidal carriers: site specific and controlled drug delivery. New Delhi: CBS Publishers and Distributors; 2010.
38. Jain S, Jain AK, Swarnakar NK, Harde H, Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen. PCT application number PCT/IB2012/001361, filed on 11/7/2012.
39. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications on drug induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013;65C:117-30.
40. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13):606-12.
41. Kallakunta VR, Bandari S, Jukanti R, Veerareddy PR. Oral self emulsifying powder of lercanidipine hydrochloride: formulation and evaluation. Powder Technol. 2012;221:375-82.
42. Van Speybroeck M, Williams HD, Nguyen T-H, Anby MU, Porter CJH, Augustijns P. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier. Mol Pharmaceutics. 2012;9(9):2750-60.
43. Zhou L, Yang L, Tilton S, Wang J. Development of a high throughput equilibrium solubility assay using miniaturized shake flask method in early drug discovery. J Pharm Sci. 2007;96(11):3052-71.
44. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329(1-2):166-72.
45. Jain S, Chauhan DS, Jain AK, Swarnakar NK, Harde H, Mahajan RR, Kumar D, Valvi PK, Das M, Datir SR, Thanki K. Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle. Indian Patent Application No 2559/DEL/2011 filed on September 06, 2011.
46. ICH Q1A(R2): Stability testing of new drug substances and products Q1A(R2), ICH harmonized tripartite guideline; Step 4 version: February 6, 2003.
47. Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008;355(1):269-76.
48. Sha X, Yan G, Wu Y, Li J, Fang X. Effect of self-microemulsifying drug delivery systems containing labrasol on tight junctions in caco-2 cells. Eur J Pharm Sci. 2005;24(5):477-86.
49. Lin Y-H, Chung C-K, Chen C-T, Liang H-F, Chen S-C, Sung H-W. Preparation of nanoparticles composed of chitosan/poly-γ-glutamic acid and evaluation of their permeability through caco-2 cells. Biomacromolecules. 2005;6(2):1104-12.
50. Neslihan Gursoy R, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173-82.
51. Moyano MA, Broussalis AM, Segall AI. Thermal analysis of lipoic acid and evaluation of the compatibility with excipientes. J Thermal Anal Calorimet. 2010;99(2):631-7.
52. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233-46.
53. Li W, Yi S, Wang Z, Chen S, Xin S, Xie J, et al. Self-nanoemulsifying drug delivery system of persimmon leaf extract: optimization and bioavailability studies. Int J Pharm. 2011;420(1):161-71.
54. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999;16(5):461-521.
55. Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS Pharm Sci Tech. 2009;10(1):69-76.
56. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227-43.
57. Ahnazarova SL, Kafarov VVAE, Mackovskij VM, Rep'ev AP. Experiment optimization in chemistry and chemical engineering. Mir Publishers; 1982, Moscow.
58. Oh SJ, Kim O, Lee JS, Kim J, Kim MR, Choi HS, et al. Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food Chem Toxicol. 2010;48(11):3227-34.
59. Oh DH, Kang JH, Kim DW, Lee BJ, Kim JO, Yong CS, et al. Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm. 2011;420(2):412-8.
60. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm. 2006;313(1):144-9.
61. Levin MS, Talkad VD, Gordon JI, Stenson WF. Trafficking of exogenous fatty acids within caco-2 cells. J Lipid Res. 1992;33(1):9-19.
62. Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702-16.